1. Home
  2. AGEN vs HELP Comparison

AGEN vs HELP Comparison

Compare AGEN & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$5.00

Market Cap

208.2M

Sector

Health Care

ML Signal

HOLD

Logo Cybin Inc. Common Stock

HELP

Cybin Inc. Common Stock

N/A

Current Price

$7.27

Market Cap

233.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AGEN
HELP
Founded
1994
N/A
Country
United States
Canada
Employees
81
50
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
208.2M
233.0M
IPO Year
1999
N/A

Fundamental Metrics

Financial Performance
Metric
AGEN
HELP
Price
$5.00
$7.27
Analyst Decision
Buy
Strong Buy
Analyst Count
2
2
Target Price
$14.50
$51.50
AVG Volume (30 Days)
8.0M
1.5M
Earning Date
05-12-2026
07-01-2026
Dividend Yield
N/A
N/A
EPS Growth
100.00
N/A
EPS
1.02
N/A
Revenue
$42,877,086.00
N/A
Revenue This Year
$107.63
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$4.95
N/A
Revenue Growth
89.95
N/A
52 Week Low
$2.71
$3.76
52 Week High
$8.70
$8.55

Technical Indicators

Market Signals
Indicator
AGEN
HELP
Relative Strength Index (RSI) 65.37 71.00
Support Level $3.16 $5.77
Resistance Level N/A $8.55
Average True Range (ATR) 0.63 0.47
MACD 0.21 0.07
Stochastic Oscillator 35.63 91.81

Price Performance

Historical Comparison
AGEN
HELP

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

About HELP Cybin Inc. Common Stock

Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.

Share on Social Networks: